Xiamen Humanity Hospital
Larynx cancer treatment cost in China typically includes diagnostics like CT of the chest, which runs $300 to $600, and surgical interventions like a laryngectomy costing $19,200 to $34,800. Total expenses depend on the cancer stage, hospital tier, and chosen therapy approach. International patients often save approximately 75-80% compared to the United States. Guangzhou and Xiamen are the primary medical hubs for this treatment.
Typical Larynx Cancer Treatment Costs in China
Bookimed Expert Insight: Advanced stage patients seeking alternatives to traditional chemotherapy find high value in China. Fuda Cancer Hospital specializes in cryosurgery and NanoKnife technologies for late-stage cases. For those requiring precise radiation, Xiamen Humanity Hospital offers expert IMRT and SBRT protocols. This is overseen by highly decorated oncologists like Professor Liu Shi Xin. Multi-day packages at JCI-accredited centers often include surgery, diagnostics, and translation services. These facilities provide comprehensive care at a fraction of Western costs.
| China | Turkey | Austria | |
| Throat cancer operation | from $18,500 | from $10,000 | from $30,000 |
| Radiotherapy for throat cancer | from $14,000 | from $3,250 | from $6,892 |
| Proton-beam therapy | from $36,500 | from $1,500 | from $80,000 |
| Laser surgery for laryngeal cancer | from $6,800 | from $8,000 | from $15,000 |
| Chemotherapy for larynx cancer | from $12,000 | from $5,000 | from $12,000 |
Chief physician and professor. Grade 1 Expert at the Cancer Center, West China Hospital, Sichuan University (ranked No. 2 in China). Completed a postdoctoral fellowship in interventional radiology at the Chinese PLA General Hospital. Leads multidisciplinary team (MDT) care for complex tumors. Expert in minimally invasive interventional oncology for liver, lung, and pancreatic cancers.
Accreditations: Council Member, WATA. Member of CACA and CMDA committees on intervention, ablation, radioactive seeds, and pain. In 2023, inaugural director member, Palliative Care Committee, Sichuan MDA. Editorial board member of the Chinese Journal of Interventional Imaging and Therapy. Editorial board member of the Chinese Journal of Pain Medicine.
Leads 2 provincial S&T projects and 2 NSFC projects. Has 40+ papers, with 30+ as first or corresponding author. Highest impact factor: 10.73. Hepatocellular carcinoma (HCC) cohort: TACE + lenvatinib vs TACE + sorafenib. OS 18.97 vs 10.77 months. PFS 10.6 vs 5.4 months. ORR 66.8% vs 33.3%.
Dr. He Weibing is a pioneer of argon-helium cryoablation in China with more than 20 years of frontline practice. He was a founding member of Fuda Cancer Hospital (Guangzhou). He co-founded its Minimally Invasive Tumor Treatment Center and served as Executive Deputy Director. He also helped found the Ablation Group of the China Anti-Cancer Association. He has been the primary operator in more than 10,000 procedures.
He specializes in tumor cryoablation and is proficient in 125I seed brachytherapy, with a focus on liver and lung cancers. He proposed ten argon-helium techniques. Key co-authored data include: lung cryotherapy n=508; NSCLC n=120 (CR 25.5%, PR 41.8%, 6/12/24-month survival 64%/55%/36%); pancreatic cancer n=38 (median survival 12 months). He served on editorial boards in 2008 and 2010. He has been a national trainer for Varian and Boston Scientific since 2001.
Professor Luo Xiaoping is a nationally recognized interventional radiologist and a leading authority in Western China. He began pioneering vascular interventions in the early 1990s. He helped found the Interventional Group at the Second Affiliated Hospital of Chongqing Medical University.
He has completed over 100,000 interventional procedures, including about 4,000 complex cases. His key skills include TACE for hepatocellular carcinoma, Budd–Chiari interventions, TIPS, and single-stage bilateral stenting for hilar biliary obstruction, with success rates near 100%. He has been a master’s supervisor since 2007. He has trained many physicians, guided complex cases at more than 40 major hospitals across Western China, and helped build interventional programs. He has published 32 papers as first or corresponding author (22 CSCD core, 4 Chinese core, 6 CSCD extended).
Professor Xiao Yueyong is Chief Physician in the Department of Radiological Diagnosis at the Chinese PLA General Hospital. He is a leading expert in minimally invasive interventional oncology. He serves as the inaugural President of WATA (2025–). He is President of the International (2020–) and Asian (2012–) Societies of Cryotherapy. He is also Deputy Head of the NHC Expert Group on tumour ablation regulations (2009–).
He has performed over 100,000 CT/MRI‑guided minimally invasive procedures. His work covers chemical ablation, RFA, MWA, cryoablation, and NanoKnife (IRE). He introduced and advanced NanoKnife ablation in China. He led the first national standards for tumour cryoablation and NanoKnife.
Honors include the National Special Contribution Award (Lifetime Honorary). He received First Prize from the Chinese Medicine Education Association (2021). He received two Second Prizes for Military Medical Achievements (2016, 2018) and two Second Prizes from the China Anti‑Cancer Association (2019, 2022). He was named Asian Ablation Master. His research record includes 13 Chinese patents. He is the principal investigator for four NSFC projects and one MOST subject. He has published over 200 papers, with over 110 as first or corresponding author and over 40 in SCI journals. He has led over 10 ablation guidelines or consensus statements.
Chinese hospitals use narrow-band imaging (NBI) and high-definition laryngostroboscopy to detect early-stage larynx cancer. For staging, centers utilize 3T MRI, dual-energy CT, and PET/CT scans. These protocols follow Chinese Society of Clinical Oncology (CSCO) guidelines to ensure accurate tumor mapping.
Bookimed Expert Insight: Diagnostic precision in China is driven by high patient volumes at tertiary centers. Xiamen Humanity Hospital serves around 1,000,000 patients annually. This massive scale allows specialists like Dr. Liu Shi Xin to refine staging accuracy. Major centers often integrate advanced PET/CT and MRI for complex cases before determining if voice-preserving surgery is possible.
Patient Consensus: Patients note that flexible laryngoscopy via the nose is typically the first step. They emphasize that while scans are helpful, direct laryngoscopy under anesthesia is vital for mapping and biopsy.
Voice-box preservation is standard in China through advanced surgical techniques. Leading facilities utilize partial laryngectomies and transoral laser surgery to remove tumors while protecting speech. Highly specialized teams also perform laryngeal transplants and subtotal reconstructions. These methods prioritize maintaining natural breathing and swallowing functions.
Bookimed Expert Insight: Patient volume significantly impacts surgical precision in China. Xiamen Humanity Hospital serves around 1,000,000 patients annually. High-volume centers often possess greater expertise in complex head-and-neck reconstructions. JCI-accredited facilities like Fuda Cancer Hospital focus on minimally invasive alternatives to radical surgery. This high caseload helps surgeons refine organ-preserving techniques that smaller clinics may not master.
Patient Consensus: Patients emphasize that voice-box preservation is possible but often results in a weaker or hoarser voice. Many suggest seeking second opinions at major cancer centers to confirm if a partial removal is oncologically safe.
Proton beam therapy is available and clinically safe for laryngeal cancer in specialized Chinese oncology centers. This advanced radiation targets tumors with extreme precision using the Bragg Peak effect. It stops at a defined depth. This prevents radiation from exiting through healthy throat tissues or vocal cords.
Bookimed Expert Insight: Professional leadership is the most reliable quality signal in China. Xiamen Humanity Hospital is led by Dr. Liu Shi Xin. He is the Vice Chairman of the Particle Therapy Committee in China. This confirms the clinic operates at the highest national level for proton and particle treatments. This clinical integration often outweighs the mere presence of the technology itself.
Patient Consensus: Patients emphasize that voice preservation and nutrition are their top priorities. Many recommend asking how proton therapy specifically improves their anatomical plan compared to standard IMRT before starting.
Voice rehabilitation after total laryngectomy primarily involves three options: tracheoesophageal puncture (TEP), an electrolarynx, or esophageal speech. TEP with a voice prosthesis is the gold standard for natural sound. Success depends on anatomy, healing, and access to specialized speech-language pathologists.
Bookimed Expert Insight: While TEP offers the most natural speech, centers like Xiamen Humanity Hospital focus on integrated oncology. Large facilities serving 1,000,000 patients annually often have higher access to multi-disciplinary teams. Reviewing whether a center offers minimally invasive options like cryosurgery or NanoKnife is vital. These technologies at Fuda Cancer Hospital suggest a focus on tissue preservation which aids recovery.
Patient Consensus: Patients note that the electrolarynx is a vital backup during the frustrating early recovery. Many emphasize that mastering voice care, including cleaning the prosthesis and managing stoma mucus, is a daily reality.
Immunotherapy is approved and available for larynx cancer in China. The National Medical Products Administration (NMPA) has authorized several immune checkpoint inhibitors. These treatments target recurrent or metastatic head and neck squamous cell carcinoma. This classification includes squamous cell cancers of the larynx.
Bookimed Expert Insight: China has become a global leader in domestic PD-1 drug development. Clinics like Xiamen Humanity Hospital are even accredited for Phase I-IV drug trials. This means patients often access the latest immunotherapy protocols through clinical trials or early-access domestic medications. These domestic drugs frequently cost up to 85% less than international brands including nivolumab.
Patient Consensus: Patients note immunotherapy often enters the conversation quickly once surgery or radiation options are exhausted. They emphasize visiting major hubs like Guangzhou or Beijing to find oncologists experienced in these specific protocols.